Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Fig. 2

Clinical course of subject No.2. CT images of target lesions in lung at (a, b) enrollment in the study, (c, d) 4.0 months after enrollment (27 % decrease in sum of diameters), (e, f) 9.2 months after enrollment (50 % increase in sum of diameters). EMCS: Extraskeletal myxoid chondrosarcoma. ▼: Administration of trabectedin. ---: Borderline of 30 % decrease in sum of diameters

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us